Development and implementation of industrialized, fully automated high throughput screening systems.

Area of Science:

• Pharmaceutical Sciences
• Laboratory Automation
• Drug Discovery

Background:

• High-throughput screening (HTS) at Bristol-Myers Squibb relies heavily on automation.
• Increasing deck sizes and shrinking timelines necessitate more advanced automation solutions.

Purpose of the Study:

• To implement a new generation of robust and supportable automated systems for HTS.
• To address the challenges posed by growing experimental demands and tighter deadlines in drug discovery.

Main Methods:

• Evaluation and selection of appropriate hardware and software for automated systems.
• Development of in-house automation expertise and support structures.
• Integration of new automated systems into existing HTS workflows.

Main Results:

• Successful implementation of fast, flexible, and industrialized automation systems.
• Establishment of a strong in-house support structure for the new automation platforms.
• Demonstrated capability to meet current and future HTS requirements.

Conclusions:

• The new generation of automated systems effectively addresses HTS challenges.
• In-house expertise and robust infrastructure are crucial for sustainable automation in drug discovery.
• The implemented solutions provide a scalable platform for future screening needs.